FMP
Jul 18, 2024 12:18 PM - Davit Kirakosyan
Image credit: FMP
Johnson & Johnson (NYSE:JNJ) shares rose more than 3% on Wednesday after the company reported impressive second-quarter results, surpassing Wall Street expectations for both earnings and revenue.
The healthcare giant delivered an EPS of $2.82, beating analyst forecasts by $0.10, and generated revenue of $22.45 billion, exceeding the consensus estimate of $22.34 billion. This performance marks a 4.3% increase in reported sales growth and a 6.6% rise in operational growth.
Despite a 5.9% decline in reported EPS due to one-time special charges, Johnson & Johnson's adjusted EPS rose by 10.2%. The company also reported a 7.1% increase in operational sales, excluding the impact of currency translation and the COVID-19 vaccine.
Chairman and CEO Joaquin Duato credited the strong quarter to the company's emphasis on innovation and advancing its product pipeline, highlighting key developments with TREMFYA, RYBREVANT, and the VARIPULSE platform.
The Innovative Medicine segment saw an 8.8% growth in worldwide operational sales, excluding the COVID-19 vaccine, driven by robust performance in Oncology and Immunology. The MedTech segment also demonstrated strength, with a 4.4% increase in worldwide operational sales, mainly due to gains in electrophysiology and wound closure products.
Looking ahead, Johnson & Johnson revised its full-year 2024 operational sales guidance upward, reflecting the acquisition of Shockwave Medical and adjustments to its adjusted operational EPS guidance based on improved performance and recent strategic acquisitions. The company now forecasts a full-year EPS of $10.05, slightly above the Street estimate of $10.01.
May 14, 2024 11:41 AM - Sanzhi Kobzhan
A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...
May 16, 2024 8:06 PM - Gordon Thompson
On Thursday, May 16, 2024, Deutsche Bank upgraded its rating on NASDAQ:ASTS to Buy, maintaining a hold position. At the time of the announcement, ASTS was trading at $4.03. This decision was accompanied by an increase in the price target for AST SpaceMobile, raised to $22 from $19, as detailed in a ...
May 24, 2024 9:30 AM - Rajnish Katharotiya
Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...